The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at
preventing the atherothrombotic complications in patients with a variety of coronary artery …

Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …

Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

Background Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the
standard of care after percutaneous coronary intervention (PCI) for patients with atrial …

Background There are limited data from randomized trials evaluating the use of
antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease …

Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the
prevention of atherothrombotic events in patients with acute coronary syndromes and for …

The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing
percutaneous coronary intervention with stent implantation represents a challenge in clinical …

Abstract The Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines
Committee provides periodic reviews of new data to produce focused updates that address …

In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …